ET
The startup develops biopharmaceutical technology that utilizes a chromatography-free, modular, and continuous process for monoclonal antibody production and viral vector separation. This approach significantly lowers capital and operating expenditures for biologics manufacturing plants, allowing biopharma companies to dynamically adjust production capacity.
Updated 18 months ago
Funding
$5.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFunding rounds are not available yet.
Founders
Product
Features
- The startup develops biopharmaceutical technology that utilizes a chromatography-free, modular, and continuous process for monoclonal antibody production and viral vector separation. This approach significantly lowers capital and operating expenditures for biologics manufacturing plants, allowing biopharma companies to dynamically adjust production capacity.